Back to Results

Abbott Laboratories (ABT)

Abbott Laboratories is a common stock listing on the NYSE representing an ordinary equity interest in Abbott Laboratories, a global healthcare company founded in 1888 and based in Abbott Park, Illinois. Through its subsidiaries, the company develops, manufactures, and markets healthcare products worldwide across four operating segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its portfolio includes branded and generic pharmaceuticals, diagnostic systems and tests, infant formula and other nutrition products, cardiovascular and diabetes care devices, and neuromodulation products for chronic pain and movement disorders. Abbott also supplies laboratory, transfusion medicine, molecular diagnostics, point-of-care, and rapid testing solutions used in clinical and laboratory settings.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-ABT
$112.65
11.6% Upside
Fair
$118.54
17.4% Upside
Fair
Good
July 15, 2026
August 17, 2026
2.52
2.5%
October 21, 2026
32.6x
3.4x
3.8x
177.1 B
203.5 B
16.2%
99.4%
—
—
136.6%
Send a message
Valuation • Fair Value

Abbott Laboratories (NYSE-ABT) Fair Value by Valuation Model

Compare the primary fair value estimate for Abbott Laboratories (NYSE-ABT) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$112.65

Estimated upside of 11.6% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$113.85

Discounted cash flow valuation reference.

Ben Graham Formula Value

$34.41

Classic Ben Graham valuation formula reference.

DDM Fair Value

$135.82

Dividend discount model valuation reference.

EPV Fair Value

$57.75

Earnings power value estimate.

Comps Fair Value

$112.88

Comparable-company valuation reference.

Analyst Price Target

$118.54

Analysts imply upside of 17.4%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Abbott Laboratories (NYSE-ABT) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Abbott Laboratories (NYSE-ABT)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

46.585 B

Current operating scale indicator.

Revenue Forecast

50.315 B

Forward revenue estimate.

EBITDA

11.867 B

Current operating profitability reference.

EBITDA Forecast

13.219 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Abbott Laboratories (NYSE-ABT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Abbott Laboratories (NYSE-ABT)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

Not available

Data is currently unavailable.

FCF / Net Income

136.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Abbott Laboratories (NYSE-ABT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Abbott Laboratories (NYSE-ABT)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

October 21, 2026

Days to Earnings

92

Dividend Payment Date

August 17, 2026

Ex-Dividend Date

July 15, 2026

Dividend Yield

2.5%

Income yield reference.

Upcoming Dividend

2.52

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Abbott Laboratories (NYSE-ABT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Abbott Laboratories (NYSE-ABT) Stock Forecast & Technical Outlook

Review Abbott Laboratories (NYSE-ABT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Abbott Laboratories (NYSE-ABT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Abbott Laboratories (NYSE-ABT) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Abbott Laboratories (NYSE-ABT) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Abbott Laboratories (NYSE-ABT) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Abbott Laboratories (NYSE-ABT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Abbott Laboratories (NYSE-ABT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Abbott Laboratories (NYSE-ABT) has a Buy consensus, with 16 buy, 7 hold and 0 sell recommendations in the current data set.

Buy 16
Hold 7
Sell 0
FAQ • Fast Investor Answers

Abbott Laboratories (NYSE-ABT) Stock FAQ

Quick answers about Abbott Laboratories (NYSE-ABT) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$112.65
Estimated upside 11.6%
Valuation Rating
Undervalued
Estimated upside of 11.6%
Analyst Target
$118.54
Implied upside 17.4%
Financial Health
Good
Current financial-health read

The current fair value estimate for Abbott Laboratories (NYSE-ABT) is $112.65. This implies an estimated upside of 11.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 11.6% versus the current market price.

The available analyst price target for Abbott Laboratories (NYSE-ABT) is $118.54. The analyst target implies estimated upside of 17.4%.

The current financial health read for Abbott Laboratories (NYSE-ABT) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Abbott Laboratories (NYSE-ABT) is October 21, 2026.

Based on the current data, dividend yield is 2.5%, upcoming dividend amount is 2.52, ex-dividend date is July 15, 2026, payment date is August 17, 2026.

The current P/E ratio listed for Abbott Laboratories (NYSE-ABT) is 32.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Abbott Laboratories is 177.1 B.

The current enterprise value listed for Abbott Laboratories is 203.5 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Abbott Laboratories is NYSE-ABT, and the stock is listed on NYSE.

Abbott Laboratories (NYSE-ABT) is listed on NYSE.

The current debt-to-total-capital ratio listed for Abbott Laboratories is 16.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Abbott Laboratories is 99.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)